The FDA approved adrabetadex (Lembaz) injection for adult and pediatric patients with infantile-onset Niemann-Pick disease type C, making it the first treatment demonstrated to reduce mortality risk in this fatal genetic disorder. Clinical data showed adrabetadex decreased mortality risk by 55% and extended median overall survival from 4.9 to 8.5 years. While existing approved therapies like Miplyffa and Aqneursa fail to reduce mortality, adrabetadex carries a boxed warning for permanent hearing loss.
FDA approval details and administration
- ▪Adrabetadex is administered by a trained healthcare provider as an intrathecal injection every 2 weeks
- ▪The FDA approved adrabetadex injection for adult and pediatric patients weighing at least 15 lb (7 kg) with infantile-onset Niemann-Pick disease type C whose neurological symptoms began before age 6
- ▪Mandos, LLC, a subsidiary of Beren Therapeutics, received the FDA approval for adrabetadex, which previously gained Breakthrough Therapy designation in December 2025
Reactions to adrabetadex approval
- ▪National Niemann-Pick Disease Foundation Executive Director Heather Moran-Teal stated that Lembaz represents an important step forward carrying profound hope for families who know how precious time can be
- ▪Acting FDA Commissioner Kyle Diamantas stated that the approval of adrabetadex marks an important milestone as the first treatment shown to help adults and children with Niemann-Pick disease type C live longer
Efficacy and survival benefit of adrabetadex
- ▪The survival benefit associated with adrabetadex persisted regardless of whether Niemann-Pick disease type C patients were also taking miglustat
- ▪In 36 Niemann-Pick disease type C patients across three clinical studies and an expanded access program, adrabetadex was associated with a 55% mortality risk reduction and median overall survival of 8.5 years versus 4.9 years in matched controls
Safety profile and warnings
- ▪Prescribing information for adrabetadex carries warnings for ataxia and fatigue, alongside a boxed warning for hearing impairment including permanent hearing loss requiring baseline and regular hearing evaluations
- ▪The most common adverse events reported in 25% or more of patients taking adrabetadex include hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough
Disease characteristics and prognosis
- ▪Infantile-onset Niemann-Pick disease type C affects approximately 475 American children—roughly half of Americans living with the disease—causing progressive neurodegeneration, loss of motor control, coordination, and swallow function
- ▪Patients with Niemann-Pick disease type C whose symptoms emerge before age 2 years have a mean age at death of about 5.6 years, while those with onset between ages 2 and 5 years have a mean age at death of about 13.4 years
- ▪Niemann-Pick disease type C is a rare inherited lysosomal storage disorder affecting roughly one in 150,000 people that impairs the body's ability to transport and metabolize intracellular cholesterol and other lipids
Existing treatments for Niemann-Pick disease type C
- ▪Miglustat (Zavesca) is a substrate reduction therapy commonly used off-label in the United States for Niemann-Pick disease type C
- ▪Two other approved treatments exist for Niemann-Pick disease type C—arimoclomol (Miplyffa) and levacetylleucine (Aqneursa)—but neither has been associated with a reduced risk of death, and both carry age or weight restrictions
Story comments
Loading comments…